HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pauwels, S. Articles by Jamar, F. Search for Related Content PubMed PubMed Citation Articles by Pauwels, S. Articles by Jamar, F.

Practical Dosimetry of Peptide Receptor Radionuclide Therapy with ⁹⁰Y-Labeled Somatostatin Analogs

¹ Centre de Médecine Nucléaire, Université Catholique de Louvain, Brussels, Belgium
² Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
³ Lee Moffitt Cancer Center, University of South Florida, Tampa, Florida

The challenge for internal therapy is to deliver the highest possible dose to the tumor while sparing normal organs from damage. Currently, the potential risk of kidney and red marrow toxicity limits the amount of radioactivity that may be administered. An accurate dosimetry method that would provide reliable dose estimates to these critical organs and to tumors before therapy would allow the clinician to plan a specific therapeutic regimen and also select those patients who would benefit the most from treatment. The dosimetry for ⁹⁰Y-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-D-Phe¹-Tyr³-octreotide is usually based on quantitative imaging at different time points that provides information on activity retention in organs over time and on stylized models representing average individuals. Because the therapeutic agent labeled with ⁹⁰Y is not suitable for quantitative imaging, the peptide surrogate labeled with the positron emitter ⁸⁶Y can be considered the most appropriate tracer for measuring distribution and retention of the radiopharmaceutical over time. Dose calculations in target organs are generally performed using the MIRDOSE program, in which S values from source to target are integrated. Significant improvement of dose estimates may be achieved by introducing patient-specific adjustments to the standard models. The use of individual kidney volumes assessed by CT instead of the use of a fixed volume for males and females may significantly improve the determination of kidney radiation doses. The use of actual CT-derived tumor volumes has also shown a dose–efficacy relationship. Additional improvements in this field include the validation and use of an ¹¹¹In surrogate to avoid the complexity of ⁸⁶Y use and the consideration of radiobiologic parameters, such as fractionation effects and the specific biologic efficacy of internally deposited radiation, which are probably underestimated using currently available methods.

Key Words: dosimetry • ⁹⁰Y-DOTA-Tyr³-octreotide • radionuclide therapy • oncology

This article has been cited by other articles:

				M. Cremonesi, M. Ferrari, L. Bodei, G. Tosi, and G. Paganelli Dosimetry in Peptide Radionuclide Receptor Therapy: A Review J. Nucl. Med., September 1, 2006; 47(9): 1467 - 1475. [Abstract] [Full Text] [PDF]

				M. T. Madsen, D. L. Bushnell, M. E. Juweid, Y. Menda, M. S. O'Dorisio, T. O'Dorisio, and I. M. Besse Potential Increased Tumor-Dose Delivery with Combined 131I-MIBG and 90Y-DOTATOC Treatment in Neuroendocrine Tumors: A Theoretic Model J. Nucl. Med., April 1, 2006; 47(4): 660 - 667. [Abstract] [Full Text] [PDF]

				G A Kaltsas, D Papadogias, P Makras, and A B Grossman Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues Endocr. Relat. Cancer, December 1, 2005; 12(4): 683 - 699. [Abstract] [Full Text] [PDF]

				L. R. Perk, G. W.M. Visser, M. J.W.D. Vosjan, M. Stigter-van Walsum, B. M. Tijink, C. R. Leemans, and G. A.M.S. van Dongen 89Zr as a PET Surrogate Radioisotope for Scouting Biodistribution of the Therapeutic Radiometals 90Y and 177Lu in Tumor-Bearing Nude Mice After Coupling to the Internalizing Antibody Cetuximab J. Nucl. Med., November 1, 2005; 46(11): 1898 - 1906. [Abstract] [Full Text] [PDF]

				G. Sgouros Dosimetry of Internal Emitters J. Nucl. Med., January 1, 2005; 46(1_suppl): 18S - 27S. [Abstract] [Full Text] [PDF]

				E. P. Krenning, R. Valkema, D. J. Kwekkeboom, W. W. de Herder, C. H.J. van Eijck, M. de Jong, S. Pauwels, and J.-C. Reubi Molecular Imaging as In Vivo Molecular Pathology for Gastroenteropancreatic Neuroendocrine Tumors: Implications for Follow-Up After Therapy J. Nucl. Med., January 1, 2005; 46(1_suppl): 76S - 82S. [Abstract] [Full Text] [PDF]

				R. Valkema, S. A. Pauwels, L. K. Kvols, D. J. Kwekkeboom, F. Jamar, M. de Jong, R. Barone, S. Walrand, P. P.M. Kooij, W. H. Bakker, et al. Long-Term Follow-Up of Renal Function After Peptide Receptor Radiation Therapy with 90Y-DOTA0,Tyr3-Octreotide and 177Lu-DOTA0, Tyr3-Octreotate J. Nucl. Med., January 1, 2005; 46(1_suppl): 83S - 91S. [Abstract] [Full Text] [PDF]

				R. Barone, F. Borson-Chazot, R. Valkema, S. Walrand, F. Chauvin, L. Gogou, L. K. Kvols, E. P. Krenning, F. Jamar, and S. Pauwels Patient-Specific Dosimetry in Predicting Renal Toxicity with 90Y-DOTATOC: Relevance of Kidney Volume and Dose Rate in Finding a Dose-Effect Relationship J. Nucl. Med., January 1, 2005; 46(1_suppl): 99S - 106S. [Abstract] [Full Text] [PDF]